"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Descriptor ID |
D000914
|
MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 5 | 5 | 10 |
1995 | 5 | 3 | 8 |
1996 | 4 | 7 | 11 |
1997 | 1 | 5 | 6 |
1998 | 3 | 10 | 13 |
1999 | 3 | 7 | 10 |
2000 | 2 | 5 | 7 |
2001 | 0 | 5 | 5 |
2002 | 5 | 11 | 16 |
2003 | 7 | 9 | 16 |
2004 | 3 | 13 | 16 |
2005 | 10 | 16 | 26 |
2006 | 6 | 7 | 13 |
2007 | 2 | 12 | 14 |
2008 | 7 | 14 | 21 |
2009 | 5 | 10 | 15 |
2010 | 3 | 9 | 12 |
2011 | 9 | 14 | 23 |
2012 | 10 | 13 | 23 |
2013 | 16 | 8 | 24 |
2014 | 14 | 15 | 29 |
2015 | 22 | 12 | 34 |
2016 | 12 | 18 | 30 |
2017 | 14 | 15 | 29 |
2018 | 21 | 13 | 34 |
2019 | 13 | 11 | 24 |
2020 | 32 | 19 | 51 |
2021 | 36 | 39 | 75 |
2022 | 7 | 61 | 68 |
2023 | 3 | 51 | 54 |
2024 | 0 | 10 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Prozone masks elevated SARS-CoV-2 antibody level measurements. PLoS One. 2024; 19(3):e0301232.
-
N6-methyladenosine modification is not a general trait of viral RNA genomes. Nat Commun. 2024 Mar 11; 15(1):1964.
-
Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association. J Med Virol. 2024 Mar; 96(3):e29505.
-
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Mar 13; 32(3):315-321.e3.
-
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 Feb 14; 229(2):327-340.
-
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 06; 32(3):722-733.
-
The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Clin Infect Dis. 2024 01 25; 78(1):217-226.
-
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nat Commun. 2024 Jan 04; 15(1):285.
-
Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.
-
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):174-185.